Pediatric Endocrinology

Understanding the Diagnosis: DEND Syndrome

At a Glance

DEND syndrome is a rare genetic condition that combines neonatal diabetes with developmental delay and seizures. Changes in KCNJ11 or ABCC8 can affect KATP channels in the pancreas and brain, so genetic testing helps guide treatment and specialist care.

Receiving a diagnosis of neonatal diabetes combined with a rare syndrome like DEND can be a profound shock. You may feel overwhelmed by the intensive demands of managing a newborn’s blood sugar while simultaneously processing a complex genetic reality that most doctors have never encountered. It is completely normal to feel a mix of grief, anxiety, and exhaustion during this time ^[1]^[2]. This page is designed to help you orient yourself to the terms, the science, and the road ahead.

What is DEND Syndrome?

DEND syndrome is an acronym that describes a specific combination of medical challenges. Each letter stands for a part of the condition:

D: Developmental delay (challenges or delays in reaching physical, cognitive, or speech milestones)
E: Epilepsy (the occurrence of seizures)
ND: Neonatal Diabetes (diabetes that begins within the first six months of life) ^[3]^[4]

There is also a related term called iDEND, or intermediate DEND. This is considered a milder version of the syndrome ^[5]^[6]. While children with iDEND have neonatal diabetes and may have some developmental challenges, those challenges are often less severe than in classic DEND, and they may or may not experience epilepsy ^[7]^[8].

Why This Diagnosis is So Rare

If you feel like your local medical team is learning along with you, it is because DEND is exceptionally rare. It is estimated to occur in fewer than 1 per 1,000,000 people ^[4]. While neonatal diabetes itself occurs in about 1 in every 100,000 to 400,000 births, only a small fraction of those cases involve the neurological features of DEND ^[9]. Because of this rarity, care will likely involve a specialized team at a major academic or research hospital.

The Science: “Gates” in the Pancreas and Brain

To understand why one genetic change affects both blood sugar and the brain, it helps to look at KATP channels. Think of these as tiny electrical gates on the surface of cells ^[10].

In the Pancreas

In a typical body, these gates close when they sense energy (sugar) in the blood. Closing the gate sends an electrical signal that tells the pancreas to release insulin. In children with DEND, a genetic change in the KCNJ11 or ABCC8 genes (which build parts of the gate called Kir6.2 and SUR1) causes the gates to stay stuck in the “open” position ^[11]^[12]. Because the gates won’t close, the signal to release insulin is never sent, leading to high blood sugar and diabetes ^[10]^[13].

In the Brain

These same types of gates are also found in the brain, where they help regulate electrical activity ^[14]. When these gates stay open in brain cells, it can disrupt the normal electrical rhythms. This disruption is what can lead to neurological symptoms, such as seizures and developmental delays ^[14]^[15].

Moving Forward

While genetic testing is urgent and helps guide future treatment, standard medical care for blood sugar stabilization, feeding support, and seizure management will happen at the same time. Knowing the specific gene and the exact “misspelling” in the DNA is crucial because it can sometimes change the long-term treatment plan ^[16]. For some individuals with certain mutations in KCNJ11 or ABCC8, doctors may be able to transition them from insulin injections to an oral medication called a sulfonylurea, which helps “force” the gates to close ^[16]^[17].

Because DEND affects multiple systems, a multidisciplinary team is necessary, typically including:

A Pediatric Endocrinologist to manage the diabetes.
A Pediatric Neurologist to monitor brain development and manage seizures.
A Medical Geneticist to interpret the genetic findings and counsel your family ^[18]^[16].

Common questions in this guide

What does DEND syndrome mean?

DEND stands for developmental delay, epilepsy, and neonatal diabetes. The diabetes begins within the first six months of life, and children may also have seizures and delays in reaching developmental milestones. A related, milder form is called iDEND.

Which genes are linked to DEND syndrome?

DEND syndrome can result from changes in the KCNJ11 or ABCC8 genes. These genes help build KATP channels, which act like electrical gates in pancreatic and brain cells. Genetic testing identifies the specific gene change and helps the care team plan treatment.

Can a child with DEND syndrome stop insulin injections?

Some children with certain KCNJ11 or ABCC8 changes may respond to an oral medicine called a sulfonylurea, which can sometimes replace insulin. The specific mutation must be reviewed by the child’s medical team, and treatment should never be changed without medical guidance.

How are seizures and developmental delays monitored in DEND syndrome?

A pediatric neurologist can monitor seizure activity, developmental milestones, and unusual movements or behaviors. Caregivers can keep notes about changes and share them with the medical team so concerns can be evaluated promptly.

Why can DEND syndrome affect both diabetes and the brain?

KATP channels are found in both the pancreas and the brain. A gene change can keep these electrical gates open, interfering with insulin release in the pancreas and normal electrical activity in brain cells.

Which specialists care for a child with DEND syndrome?

Care often involves a pediatric endocrinologist for diabetes, a pediatric neurologist for seizures and development, and a medical geneticist for genetic results and family counseling. These specialists may coordinate care through a multidisciplinary team.

Get notified when new evidence is published on DEND syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Psychiatric morbidity in children with KCNJ11 neonatal diabetes.
Bowman P, Broadbridge E, Knight BA, et al.
Diabetic medicine : a journal of the British Diabetic Association 2016; (33(10)):1387-91 doi:10.1111/dme.13135.
PMID: 27086753
2
ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.
Landmeier KA, Lanning M, Carmody D, et al.
Pediatric diabetes 2017; (18(7)):518-523 doi:10.1111/pedi.12428.
PMID: 27555491
3
Precision therapy for Developmental delay, Epilepsy and Neonatal Diabetes syndrome in the era of genomics.
Badal S, Sondhi V, Sannalli K, et al.
Medical journal, Armed Forces India 2024; (80(Suppl 1)):S337-S340 doi:10.1016/j.mjafi.2024.01.007.
PMID: 39734857
4
Permanent Neonatal Diabetes (DEND Syndrome).
Khan SA, Parkash A, Ibrahim M
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2016; (26(11)):114-115 doi:218.
PMID: 28666500
5
Successful transition to sulfonylurea therapy in two Iraqi siblings with neonatal diabetes mellitus and iDEND syndrome due to ABCC8 mutation.
Ozsu E, Giri D, Seymen Karabulut G, Senniappan S
Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(12)):1403-1406.
PMID: 27849623
6
Case Report: When genetic diagnosis comes late: lessons from a DEND syndrome patient successfully transitioned to sulfonylurea.
Abreu GM, Bastos de Souza R, Bernardo MC, et al.
Frontiers in clinical diabetes and healthcare 2025; (6()):1654037 doi:10.3389/fcdhc.2025.1654037.
PMID: 41169283
7
Case report: Neonatal diabetes mellitus caused by KCNJ11 mutation presenting with intracranial hemorrhage.
Wu B, Xu W
Frontiers in neurology 2023; (14()):1072078 doi:10.3389/fneur.2023.1072078.
PMID: 36937531
8
First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Ioacara S, Flanagan S, Fröhlich-Reiterer E, et al.
Journal of diabetes investigation 2017; (8(5)):716-719 doi:10.1111/jdi.12620.
PMID: 28083968
9
Monogenic Forms of Diabetes Mellitus.
Gaál Z, Balogh I
Experientia supplementum (2012) 2019; (111()):385-416 doi:10.1007/978-3-030-25905-1_18.
PMID: 31588541
10
New insights into KATP channel gene mutations and neonatal diabetes mellitus.
Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM
Nature reviews. Endocrinology 2020; (16(7)):378-393 doi:10.1038/s41574-020-0351-y.
PMID: 32376986
11
Production and purification of ATP-sensitive potassium channel particles for cryo-electron microscopy.
Driggers CM, Shyng SL
Methods in enzymology 2021; (653()):121-150 doi:10.1016/bs.mie.2021.02.008.
PMID: 34099169
12
Structure of an open KATP channel reveals tandem PIP2 binding sites mediating the Kir6.2 and SUR1 regulatory interface.
Driggers CM, Kuo YY, Zhu P, et al.
Nature communications 2024; (15(1)):2502 doi:10.1038/s41467-024-46751-5.
PMID: 38509107
13
Kir6.2 channel activity is regulated by interaction of transmembrane domains 1 and 2 through I167 in the bundle-crossing gate.
Kawashima R, Meller C, Suzuki M, et al.
Physiological reports 2025; (13(15)):e70481 doi:10.14814/phy2.70481.
PMID: 40746251
14
KATP channel mutation disrupts hippocampal network activity and nocturnal gamma shifts.
Burkart ME, Kurzke J, Jacobi R, et al.
Brain : a journal of neurology 2024; (147(12)):4200-4212 doi:10.1093/brain/awae157.
PMID: 38748482
15
KATP Channel Mutations and Neonatal Diabetes.
Shimomura K, Maejima Y
Internal medicine (Tokyo, Japan) 2017; (56(18)):2387-2393 doi:10.2169/internalmedicine.8454-16.
PMID: 28824061
16
The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.
De Franco E, Flanagan SE, Houghton JA, et al.
Lancet (London, England) 2015; (386(9997)):957-63.
PMID: 26231457
17
Recent Advances in Neonatal Diabetes.
Dahl A, Kumar S
Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):355-364 doi:10.2147/DMSO.S198932.
PMID: 32104032
18
Neonatal Diabetes Mellitus.
Beltrand J, Busiah K, Vaivre-Douret L, et al.
Frontiers in pediatrics 2020; (8()):540718 doi:10.3389/fped.2020.540718.
PMID: 33102403

This page is for informational purposes only and does not constitute medical advice about DEND syndrome. Your child’s pediatric endocrinologist, neurologist, and genetics team should interpret genetic results and guide treatment.

Guide Contents